TERIFIN
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Teriflunomide
Dihydroorotate dehydrogenase inhibitor
- Fingolimod
What it measured
Main measures
1) correlation of the measured concentrations of fingolimod (including the metabolite fingolimod-phosphate) and teriflunomide (including the free fraction) with the clinical status of patients with MS
Other measures (1)
1) analysis of the relationship between the measured concentrations of fingolimod (including the fingolimod-phosphate metabolite) and teriflunomide (including the free fraction) with the concentrations of other MS biomarkers, such as plasma neurofilament light chains (“pNfL”) concentrations, vitamin D concentrations, and immune system cell concentrations, which are associated with MS
Blood or spinal fluid markers
Who could take part
MS (type not specified)
Inclusion: 1) patients diagnosed with MS, taking fingolimod or teriflunomide for at least 6 months Exclusion: 1) pediatric patients
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
correlation of the measured concentrations of fingolimod (including the fingolimod-phosphate metabolite) and teriflunomide (including the free fraction) with the clinical status of patients with MS
Loading reviews and guidelines…
Related trials
- Risk of Progressive Multifocal Leukoencephalopathy Among …
Recruiting
Still running
- TDM-MS
Phase 4 · Status unknown
No result found
- SEP-1
Recruiting
Still running
- Observational Study of the Effect of Ozanimod on Fatigue …
Stopped early
Stopped early
- Post-Authorization Safety Study for Assessment of Pregnan…
Recruiting
Still running
- Peripheral neuropathy as potential side effect in patient…
Phase 4 · Completed
No result found
History
Started
Jan 2023
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error